The past decade has provided numerous advances in the treatment of rheumatoid arthritis. As will be discussed, recent evidence of 2 medications from different classes provide reassurance as to their long-term safety and efficacy. Of key importance is that these treatment advances provide a real opportunity to achieve disease remission using a treat-to-target approach. The benefits of achieving long-term disease remission vs low disease activity are presented. Join Dr. Roy Fleischmann as he discusses this recent evidence from the American College of Rheumatology Convergence 2020 virtual annual meeting and the implications for clinical practice.

• 

  Roy M. Fleischmann, MD

  Clinical Professor of Medicine
  University of Texas Southwestern Medical Center
  Medical Director
  Metroplex Clinical Research Center
  Dallas, Texas